OM
PHAT icon

Opaleye Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Opaleye Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
+185,589
New +$2.12M 0.18% 46
2023
Q2 		– Sell
-496,000
Closed -$3.54M – 51
2023
Q1 		$3.54M Buy
496,000
+78,500
+19% +$690K 1.06% 31
2022
Q4 		$4.68M Buy
+417,500
New +$4.3M 1.63% 18

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Opaleye Management's PHAT Position: Q2 2026 in Review

Opaleye Management opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 185,589 shares worth $2.01M. The stake represents 0.18% of the portfolio and ranks #46 among its holdings. This is a return to the name: Opaleye Management previously reported a position in PHAT as recently as Q1 2023.

Opaleye Management first reported a position in PHAT in Q4 2022 and has held it in 3 quarters since. The position peaked at $4.68M in Q4 2022. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Opaleye Management held 185,589 shares of Phathom Pharmaceuticals worth $2.01M as of Q2 2026.
  • Phathom Pharmaceuticals was a new Opaleye Management position in Q2 2026.
  • Phathom Pharmaceuticals made up 0.18% of Opaleye Management's portfolio in Q2 2026, its #46 holding.
  • Opaleye Management first reported a position in Phathom Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • Opaleye Management's Phathom Pharmaceuticals position peaked at $4.68M in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.